Risk factors for ischemic antiphospholipid syndrome: A case-control study

Matus-Mayorga, Roxana; Barrera‐Vargas, Ana; Rull-Gabayet, Marina; Aguirre-Aguilar, Eduardo; Valdez-López, Martín; Espinoza-Lira, Fernando; Ramos-Ventura, Cristina; Cano-Nigenda, Vanessa; Barboza, Miguel A; Merayo-Chalico, Javier; Araúz, Antonio

doi:10.1016/j.clineuro.2021.106492

Cited by 5 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our cohort, recurrence occurred in 11.8% of the individuals with stroke. The recurrence rate was higher than that in the Euro-phospholipid cohort [5], but comparable with those found in other long-term studies [21,24]. The univariate analysis showed thrombocytopenia to be associated with a significantly decreased risk of stroke recurrence, contrary to the former study [15].…”

Section: Discussionsupporting

confidence: 84%

Stroke and Risk Factors in Antiphospholipid Syndrome

Fan,

Xu,

Zhang

et al. 2023

JPM

View full text Add to dashboard Cite

Stroke is considered one of the most common and life-threatening manifestations of antiphospholipid syndrome (APS), which leads to high mortality and permanent disability. This study investigated the prevalence and the potential risk factors of stroke in APS. We enrolled 361 APS patients retrospectively from 2009 to 2022 at Peking University People’s Hospital. Stroke was found in 25.8% (93/361) of the participants. The multivariate logistic regression showed that hypertension, diabetes, livedo reticularis, and other central nervous system involvements were significant related factors for stroke. The use of hydroxychloroquine appeared to relate to a lower incidence of stroke. During a median follow-up of 3.0 years, 11.8% (11/93) of the individuals with a previous stroke developed stroke recurrence, and thrombocytopenia seemed to be a predictor of stroke recurrence.

show abstract

Section: Discussionsupporting

confidence: 84%

Stroke and Risk Factors in Antiphospholipid Syndrome

Fan,

Xu,

Zhang

et al. 2023

JPM

View full text Add to dashboard Cite

show abstract

“…25 Additionally, 34.5% of our cases had lesions of the large vessels perforating branches. In a study of 53 patients with PAPS using the Oxfordshire Community Stroke Project classification system, clinically, the lesion was located within the posterior circulation in 22.6% of their patients, 26 whereas when taking into account multivessel disease restricted to the posterior circulation (including vertebral and basilar arteries perforating branches), we found a frequency of 42.9%. This high proportion of simultaneous involvement of several arterial territories and vessel size shows that the cerebral arterial system can be globally affected in APS.…”

Section: Discussionmentioning

confidence: 66%

“…35 As for the functional prognosis, more than 60% of patients with AIS and CVT had a good functional outcome, contrary to those who presented with an intracranial hemorrhage, as expected for the general population within the studied age group. 23,[36][37][38][39][40] Our AIS recurrence rate (16.7%) falls within the 15-37% reported among APS patients; 26,41 despite this high frequency, to date there is no reliable biomarker or prediction tool to help distinguish patients most likely to have a recurrent event. The aGAPSS is a tool that has proven to predict extracranial thrombotic events; 10,11 therefore, as there is no defined cut-off value for intracranial events, we explored by univariable analysis if there was a difference in the total score of this prediction tool between patients who had an AIS recurrence and those who did not, finding that there was no statistical difference.…”

Section: Discussionmentioning

confidence: 84%

Antiphospholipid syndrome–mediated acute cerebrovascular diseases and long-term outcomes

García‐Grimshaw

Posadas-Pinto

Jiménez‐Ruiz

et al. 2022

Lupus

View full text Add to dashboard Cite

Objectives The antiphospholipid syndrome (APS) is an autoimmune disease associated with thrombotic and non-thrombotic neurologic manifestations. APS is classified as primary (PAPS) or secondary (SAPS) when it co-exists with another autoimmune disease. We aim to describe the spectrum of acute cerebrovascular disease among patients with APS, their differences between stroke subtypes, and long-term functional outcomes. Methods Retrospective cohort study including adult (≥18 years) patients with APS followed in the stroke clinic of a tertiary-care reference center for autoimmune diseases in Mexico from 2009 to 2019. Results We studied 120 cases; 99 (82.5%) women; median age 43 years (interquartile range 35–52); 63.3% with SAPS. Demographics, comorbidities, and antiphospholipid antibodies (aPL) positivity were similar between APS type and stroke subtypes. Amongst index events, we observed 84 (70%) acute ischemic strokes (AIS), 19 (15.8%) cerebral venous thromboses (CVT), 11 (9.2%) intracerebral hemorrhages (ICH), and six (5%) subarachnoid hemorrhages (SAH). Sixty-seven (55.8%) were known patients with APS; the median time from APS diagnosis to index stroke was 46 months (interquartile range 12–96); 64.7% of intracranial hemorrhages (ICH or SAH) occurred ≥4 years after APS was diagnosed (23.5% anticoagulation-related); 63.2% of CVT cases developed before APS was diagnosed or simultaneously. Recurrences occurred in 26 (22.8%) patients, AIS, in 18 (69.2%); intracranial hemorrhage, in eight (30.8%). Long-term functional outcomes were good (modified Rankin Scale ≤2) in 63.2% of cases, during follow-up, the all-cause mortality rate was 19.2%. Conclusion We found no differences between stroke subtypes and APS types. aPL profiles were not associated with any of the acute cerebrovascular diseases described in this cohort. CVT may be an initial thrombotic manifestation of APS with low mortality and good long-term functional outcome.

show abstract

“…Antiphospholipid syndrome (APS) is an autoimmune disease defined by laboratory and clinical findings associated with arterial or venous thrombosis or obstetrical events [7][8][9]. The patients commonly present venous thromboembolism usually affecting the legs, with a prevalence of 31.7%-38.9%, but cerebral venous thrombosis is rare with a prevalence of 0.7% [5,10].…”

Section: Introductionmentioning

confidence: 99%

Cerebral Venous Thrombosis in a 17-Year-Old Female Patient: A Case Report

Casanova Rivera,

Ligua Duque,

Moreno Veloz

et al. 2023

Cureus

View full text Add to dashboard Cite

Cerebral venous thrombosis (CVT) is a rare disorder predominantly affecting young women. Clinical presentation is not specific and varies depending on the location of the thrombus. The diagnosis requires clinical suspicion with confirmation by images. Guidelines for treatment recommend heparin during the acute phase even in patients with intraparenchymal hemorrhage. It is associated with a good prognosis when diagnosed and treated promptly. We present a case of CVT and intraparenchymal hemorrhage in a 17year-old female with severe headache, nausea, vomiting, and altered mental status. The patient was diagnosed with CVT secondary to systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). She showed improvement after anticoagulation and corticosteroids.

show abstract

Risk factors for ischemic antiphospholipid syndrome: A case-control study

Cited by 5 publications

References 30 publications

Stroke and Risk Factors in Antiphospholipid Syndrome

Stroke and Risk Factors in Antiphospholipid Syndrome

Antiphospholipid syndrome–mediated acute cerebrovascular diseases and long-term outcomes

Cerebral Venous Thrombosis in a 17-Year-Old Female Patient: A Case Report

Contact Info

Product

Resources

About